Welcome to the Alexion Canada website. We opened our doors in Canada in 2009 and currently run our country operations from our office in Vaughan, ON. We are a team of dedicated professionals committed to providing life-transforming treatments to patients with severe and life-threatening rare diseases for which there are few, if any, effective treatment options.
In Canada, Soliris® (eculizumab) is approved by Health Canada for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (atypical HUS). Both PNH and atypical HUS are ultra-rare diseases that are severe, chronic, progressive and life-threatening, with a profound impact on patients, their families and society.
We are currently conducting clinical trials with Canadian researchers for rare diseases that affect the kidneys, blood, brain and other vital organs where the complement system plays a role and where current treatment options remain inadequate. Our goal is to bring new hope with our products to these underserved patient populations.
At Alexion Canada we are about making a difference in the lives of our patients and their families.
Thank you for visiting the Alexion Pharma Canada website.